Compare TWN & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TWN | FLGT |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 550.8M | 511.2M |
| IPO Year | 1994 | 2016 |
| Metric | TWN | FLGT |
|---|---|---|
| Price | $92.77 | $19.96 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $28.33 |
| AVG Volume (30 Days) | 48.6K | ★ 361.6K |
| Earning Date | 01-01-0001 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $18,730,000.00 |
| Revenue This Year | N/A | $10.09 |
| Revenue Next Year | N/A | $12.18 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $44.01 | $13.46 |
| 52 Week High | $105.09 | $31.04 |
| Indicator | TWN | FLGT |
|---|---|---|
| Relative Strength Index (RSI) | 44.65 | 65.54 |
| Support Level | $88.51 | $13.91 |
| Resistance Level | $101.61 | $19.93 |
| Average True Range (ATR) | 4.13 | 0.60 |
| MACD | -0.73 | 0.03 |
| Stochastic Oscillator | 17.44 | 97.10 |
Taiwan Fund Inc is a diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investment predominantly in equity securities listed in Taiwan stock exchange and the Republic of China. In selecting the companies for investments fund's portfolio managers will consider overall growth prospects, competitive position in the respective industry technology, research, and development, productivity, profit margins, return on investment, capital resources, government regulation, management and other factors.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.